Bayer HealthCare Pharmaceuticals, 100 Bayer Blvd, Whippany, NJ 07981, USA.
Future Oncol. 2024;20(16):1111-1121. doi: 10.2217/fon-2023-0376. Epub 2023 Sep 13.
To evaluate temporal changes in metastatic colorectal cancer (mCRC), incidence, and use of chemotherapy treatment by age group using real-world data (RWD) from the USA. A retrospective, observational study describing temporal trends in mCRC incidence and FOLFOXIRI treatment by age group using a nationwide database of commercially and Medicare Advantage-insured patients from 2010 to 2019. Incidence of mCRC increased by 22.1 and 14.9% in the 18-49 and 50-64 years cohorts, respectively, and decreased by 21.6% in the ≥65 years cohort. Overall, younger patients were more likely to receive FOLFOXIRI treatment versus older patients. The shifting age distribution of mCRC should be considered when recommending screening and treatment. Further research is needed to inform age-specific treatment guidelines.
为了评估美国真实世界数据（RWD）中转移性结直肠癌（mCRC）、发病率和化疗治疗的年龄组的时间变化。一项回顾性观察研究，使用全国性商业和医疗保险优势保险患者数据库，描述了 2010 年至 2019 年 mCRC 发病率和 FOLFOXIRI 治疗按年龄组的时间趋势。18-49 岁和 50-64 岁年龄组的 mCRC 发病率分别增加了 22.1%和 14.9%，而≥65 岁年龄组则下降了 21.6%。总体而言，年轻患者比老年患者更有可能接受 FOLFOXIRI 治疗。在推荐筛查和治疗时，应考虑 mCRC 年龄分布的变化。需要进一步的研究来为特定年龄的治疗指南提供信息。
